Is phosphodiesterase type 5 inhibitor use associated with condom breakage?

R Crosby, W L Yarber, S A Sanders, C A Graham

ABSTRACT

We tested the hypothesis that phosphodiesterase type 5 inhibitor (PDE5i) use would be associated with increased likelihood of condom breakage using an event-specific analysis. A convenience sample of 440 men completed an internet-based questionnaire that assessed variables pertaining to the last time they used condoms for penile-vaginal intercourse (PVI). A bivariate (screening) analysis was performed to identify covariates for a multivariate analysis using logistic regression. Altogether, 5.9% of the men reported breakage and 9.5% reported PDE5i use during the last time a condom was used for PVI. Among men who had used PDE5i during the last condom-protected occasion of PVI, 11.9% reported breakage compared with 5.3% of those not reporting PDE5i use. Adjusting for men's age, ethnic minority status, marital status, reported duration of PVI and alcohol use at last PVI, those using PDE5i were about four times more likely to also report condom breakage (AOR 4.02; 95% CI 1.20 to 13.48; p = 0.04). Of note, duration of PVI was independently associated with breakage (AOR 1.36; CI 1.02 to 1.83; p = 0.04). Findings suggest that PDE5i use may potentially be associated with increased odds of condom breakage among some men.

Phosphodiesterase type 5 inhibitor (PDE5i) drugs have been widely used as a treatment for erectile dysfunction. Although generally regarded as effective and safe, these drugs have also been associated with increased rates of high-risk sexual behaviour and HIV transmission in some men. Whether PDE5i increase the odds of condom breakage has not been studied. Breakage is not uncommon and largely negates the protective value of condoms relative to the prevention of pregnancy or sexually transmitted infections. Given the enhanced erections provided by PDE5i, it is plausible that condoms become more tight-fitting. Tight-fitting condoms have been associated with breakage.

MEASURES

Assessments focused on the last condom use event for PVI. Condom breakage, PDE5i use and three covariates—duration of PVI, degree of vaginal lubrication and alcohol use (previously shown to be related to condom breakage)—were assessed by asking the following questions, respectively:

Thinking about the last time you used a condom for PVI...

Q1. Did the condom break during PVI? (no, yes, I don’t know)
Q2. Did you use Viagra, Cialis or Levitra? (no, yes)
Q3. How long was your penis in the vagina? (less than a minute, 1–5, 6–10, 11–15, 16–20, 21 or more minutes)
Q4. How well lubricated was your partner’s vagina? (very well lubricated (moist and slippery), adequate lubrication (no dry feeling), not quite enough lubrication (a little dry), poorly lubricated (very dry))
Q5. Were you drinking alcoholic beverages? (no, 1–2, 3–5, more than 5 drinks; a drink equals 1 beer, glass of wine or shot of liquor)

Data analysis

Continuous covariates not meeting normality assumptions were dichotomised by a median split. Variables achieving a screening-level of bivariate significance (p < 0.15) with condom breakage or PDE5i use were entered into a multiple logistic regression model to calculate adjusted odds ratios (AOR), their 95% confidence intervals (CIs) and respective p values.

RESULTS

Characteristics of the sample

Average age was 29.6 years (SD 10.1). Breakage was reported by 26 men (5.9%) and 42 men (9.5%) reported PDE5i use. Table 1 shows descriptive information relative to the dichotomised measures.

Bivariate associations

PDE5i use, alcohol use and minority ethnicity achieved screening significance (table 1). Table 1 displays the number of men responding “yes vs no” for each variable as well as the percentage of that number who reported condom breakage. For example, 42 reported PDE5i use and 11.9% of these (n = 5) also reported breakage compared with 5.3% (n = 21) of the 398 men not using PDE5i. Men’s age and reported duration of PVI were preserved as continuous-level variables; therefore, bivariate associations were based on independent group t tests. Age did not vary between men reporting breakage (mean age = 28.1 years) and not reporting...
breakage (mean age = 29.7 years) (t = 0.78 (438); p = 0.45). However, duration of PVI score was significantly longer among those reporting breakage (mean score = 4.7) versus those not reporting breakage (mean score = 4.0; t = 2.45 (438); p = 0.015).

PDE5i users were significantly older (mean age 41.1 years) than non-users (28.4 years; t = 2.3 (438); p < 0.0001). PDE5i use was significantly more common among married men (12.9%) than single men (5.6%; p < 0.001).

### Multivariate associations

The logistic regression model using age, minority status (no/yes), single (no/yes), duration (scale 1 (less than 1 minute) to 6 (21 or more minutes)), alcohol use (no/yes) and PDE5i use (no/yes) was significant ($\chi^2$ with 6 df = 16.01; p = 0.01) and produced a satisfactory fit with the data (goodness of fit $\chi^2$ with 8 df = 9.45; p = 0.31). Minority ethnicity (AOR 2.5; 95% CI 1.04 to 6.43; p = 0.04), duration of PVI (AOR 1.56; 95% CI 1.02 to 1.83; p = 0.04) and PDE5i use (AOR 4.04; 95% CI 1.06 to 15.41; p = 0.04) achieved multivariate significance.

### DISCUSSION

In a controlled analysis, condom breakage was about four times more likely among men using PDE5i drugs. However, a previous study of an older sample found that some men still experience erection problems while trying to use condoms in spite of PDE5i use. Such findings highlight the importance of further studies, including qualitative research, to examine implications for physicians prescribing PDE5i drugs.

Findings are limited by the validity of retrospective self-report and the use of a convenience sample. Although the use of event-specific analysis adds considerable strength to the study, this feature precludes the use of a repeated measures design that would allow for within-person comparisons as a function of PDE5i use. Given support from further investigations regarding PDE5i use and condom breakage, counselling could emphasise the following messages: 1) use condoms large enough to fit the enhanced erections that may be experienced and 2) understand that longer duration of intercourse may be associated with increased risk of breakage. Because not all PDE5i use is through prescription, these implications may also be relevant in sexually transmitted infections clinics.

### Key messages

- Phosphodiesterase type 5 inhibitor (PDE5i) use may be a risk factor for condom breakage.
- Given further support for the hypothesis that PDE5i use is a risk factor for condom breakage, counselling messages to men being prescribed these drugs may need to include objectives designed to avert breakage.
- Men attending sexually transmitted infections clinics and reporting PDE5i use may also benefit from counselling designed to reduce their risk of condom breakage.

### REFERENCES

Is phosphodiesterase type 5 inhibitor use associated with condom breakage?

R Crosby, W L Yarber, S A Sanders, et al.

*Sex Transm Infect* 2009 85: 404-405
doi: 10.1136/sti.2009.036012

Updated information and services can be found at:
http://sti.bmj.com/content/85/5/404.full.html

These include:

**References**
This article cites 10 articles, 4 of which can be accessed free at:
http://sti.bmj.com/content/85/5/404.full.html#ref-list-1

Article cited in:
http://sti.bmj.com/content/85/5/404.full.html#related-urls

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Reproductive medicine (27677 articles)
- Condoms (224 articles)
- Screening (epidemiology) (6479 articles)
- Screening (public health) (6501 articles)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/